6VUM image
Entry Detail
PDB ID:
6VUM
EMDB ID:
Title:
Structure of nevanimibe-bound human tetrameric ACAT1
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-02-16
Release Date:
2020-05-13
Method Details:
Experimental Method:
Resolution:
3.67 Å
Aggregation State:
CELL
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Sterol O-acyltransferase 1
Chain IDs:A, B, C, D
Chain Length:558
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Structure of nevanimibe-bound tetrameric human ACAT1.
Nature 581 339 343 (2020)
PMID: 32433613 DOI: 10.1038/s41586-020-2295-8

Abstact

Cholesterol is an essential component of mammalian cell membranes, constituting up to 50% of plasma membrane lipids. By contrast, it accounts for only 5% of lipids in the endoplasmic reticulum (ER)1. The ER enzyme sterol O-acyltransferase 1 (also named acyl-coenzyme A:cholesterol acyltransferase, ACAT1) transfers a long-chain fatty acid to cholesterol to form cholesteryl esters that coalesce into cytosolic lipid droplets. Under conditions of cholesterol overload, ACAT1 maintains the low cholesterol concentration of the ER and thereby has an essential role in cholesterol homeostasis2,3. ACAT1 has also been implicated in Alzheimer's disease4, atherosclerosis5 and cancers6. Here we report a cryo-electron microscopy structure of human ACAT1 in complex with nevanimibe7, an inhibitor that is in clinical trials for the treatment of congenital adrenal hyperplasia. The ACAT1 holoenzyme is a tetramer that consists of two homodimers. Each monomer contains nine transmembrane helices (TMs), six of which (TM4-TM9) form a cavity that accommodates nevanimibe and an endogenous acyl-coenzyme A. This cavity also contains a histidine that has previously been identified as essential for catalytic activity8. Our structural data and biochemical analyses provide a physical model to explain the process of cholesterol esterification, as well as details of the interaction between nevanimibe and ACAT1, which may help to accelerate the development of ACAT1 inhibitors to treat related diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures